BIOMAT Database Logo BIOMAT Database Logo

cGAS-STING drives the IL-6-dependent survival of chromosomally instable cancers. 2022

Christy Hong, and Michael Schubert, and Andréa E Tijhuis, and Marta Requesens, and Maurits Roorda, and Anouk van den Brink, and Lorena Andrade Ruiz, and Petra L Bakker, and Tineke van der Sluis, and Wietske Pieters, and Mengting Chen, and René Wardenaar, and Bert van der Vegt, and Diana C J Spierings, and Marco de Bruyn, and Marcel A T M van Vugt, and Floris Foijer
European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Chromosomal instability (CIN) drives cancer cell evolution, metastasis and therapy resistance, and is associated with poor prognosis1. CIN leads to micronuclei that release DNA into the cytoplasm after rupture, which triggers activation of inflammatory signalling mediated by cGAS and STING2,3. These two proteins are considered to be tumour suppressors as they promote apoptosis and immunosurveillance. However, cGAS and STING are rarely inactivated in cancer4, and, although they have been implicated in metastasis5, it is not known why loss-of-function mutations do not arise in primary tumours4. Here we show that inactivation of cGAS-STING signalling selectively impairs the survival of triple-negative breast cancer cells that display CIN. CIN triggers IL-6-STAT3-mediated signalling, which depends on the cGAS-STING pathway and the non-canonical NF-κB pathway. Blockade of IL-6 signalling by tocilizumab, a clinically used drug that targets the IL-6 receptor (IL-6R), selectively impairs the growth of cultured triple-negative breast cancer cells that exhibit CIN. Moreover, outgrowth of chromosomally instable tumours is significantly delayed compared with tumours that do not display CIN. Notably, this targetable vulnerability is conserved across cancer types that express high levels of IL-6 and/or IL-6R in vitro and in vivo. Together, our work demonstrates pro-tumorigenic traits of cGAS-STING signalling and explains why the cGAS-STING pathway is rarely inactivated in primary tumours. Repurposing tocilizumab could be a strategy to treat cancers with CIN that overexpress IL-6R.

UI MeSH Term Description Entries
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D009713 Nucleotidyltransferases A class of enzymes that transfers nucleotidyl residues. EC 2.7.7. Nucleotidyltransferase
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB
D043171 Chromosomal Instability An increased tendency to acquire CHROMOSOME ABERRATIONS when various processes involved in chromosome replication, repair, or segregation are dysfunctional. Chromosomal Stability,Chromosome Instability,Chromosome Stability,Chromosomal Instabilities,Chromosomal Stabilities,Chromosome Instabilities,Chromosome Stabilities,Instabilities, Chromosomal,Instabilities, Chromosome,Instability, Chromosomal,Instability, Chromosome,Stabilities, Chromosomal,Stabilities, Chromosome,Stability, Chromosomal,Stability, Chromosome
D050796 STAT3 Transcription Factor A signal transducer and activator of transcription that mediates cellular responses to INTERLEUKIN-6 family members. STAT3 is constitutively activated in a variety of TUMORS and is a major downstream transducer for the CYTOKINE RECEPTOR GP130. APRF Transcription Factor,Acute-Phase Response Factor,IL6-Response Factor,LIF-Response Factor,STAT3 Protein,STAT3a Transcription Factor,STAT3b Transcription Factor,Signal Transducer and Activator of Transcription 3,Stat3alpha Transcription Factor,Stat3beta Transcription Factor,Acute Phase Response Factor,IL6 Response Factor,LIF Response Factor,Response Factor, Acute-Phase,Transcription Factor, APRF,Transcription Factor, STAT3,Transcription Factor, STAT3a,Transcription Factor, STAT3b,Transcription Factor, Stat3alpha,Transcription Factor, Stat3beta
D058492 Drug Repositioning The deliberate and methodical practice of finding new applications for existing drugs. Drug Repurposing,Drug Rescue,Repositioning, Drug,Repurposing, Drug,Rescue, Drug

Related Publications

Christy Hong, and Michael Schubert, and Andréa E Tijhuis, and Marta Requesens, and Maurits Roorda, and Anouk van den Brink, and Lorena Andrade Ruiz, and Petra L Bakker, and Tineke van der Sluis, and Wietske Pieters, and Mengting Chen, and René Wardenaar, and Bert van der Vegt, and Diana C J Spierings, and Marco de Bruyn, and Marcel A T M van Vugt, and Floris Foijer
The cGAS-STING pathway: a therapeutic target in chromosomally unstable cancers.
January 2023, Signal transduction and targeted therapy,
Christy Hong, and Michael Schubert, and Andréa E Tijhuis, and Marta Requesens, and Maurits Roorda, and Anouk van den Brink, and Lorena Andrade Ruiz, and Petra L Bakker, and Tineke van der Sluis, and Wietske Pieters, and Mengting Chen, and René Wardenaar, and Bert van der Vegt, and Diana C J Spierings, and Marco de Bruyn, and Marcel A T M van Vugt, and Floris Foijer
Extracellular vesicles from A23187-treated neutrophils cause cGAS-STING-dependent IL-6 production by macrophages.
January 2022, Frontiers in immunology,
Christy Hong, and Michael Schubert, and Andréa E Tijhuis, and Marta Requesens, and Maurits Roorda, and Anouk van den Brink, and Lorena Andrade Ruiz, and Petra L Bakker, and Tineke van der Sluis, and Wietske Pieters, and Mengting Chen, and René Wardenaar, and Bert van der Vegt, and Diana C J Spierings, and Marco de Bruyn, and Marcel A T M van Vugt, and Floris Foijer
cGAS-STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers.
October 2022, Trends in cancer,
Christy Hong, and Michael Schubert, and Andréa E Tijhuis, and Marta Requesens, and Maurits Roorda, and Anouk van den Brink, and Lorena Andrade Ruiz, and Petra L Bakker, and Tineke van der Sluis, and Wietske Pieters, and Mengting Chen, and René Wardenaar, and Bert van der Vegt, and Diana C J Spierings, and Marco de Bruyn, and Marcel A T M van Vugt, and Floris Foijer
IL6 Signaling Enables Survival of Chromosomally Instable Cancer Cells.
August 2022, Cancer discovery,
Christy Hong, and Michael Schubert, and Andréa E Tijhuis, and Marta Requesens, and Maurits Roorda, and Anouk van den Brink, and Lorena Andrade Ruiz, and Petra L Bakker, and Tineke van der Sluis, and Wietske Pieters, and Mengting Chen, and René Wardenaar, and Bert van der Vegt, and Diana C J Spierings, and Marco de Bruyn, and Marcel A T M van Vugt, and Floris Foijer
cGAS-STING drives ageing-related inflammation and neurodegeneration.
August 2023, Nature,
Christy Hong, and Michael Schubert, and Andréa E Tijhuis, and Marta Requesens, and Maurits Roorda, and Anouk van den Brink, and Lorena Andrade Ruiz, and Petra L Bakker, and Tineke van der Sluis, and Wietske Pieters, and Mengting Chen, and René Wardenaar, and Bert van der Vegt, and Diana C J Spierings, and Marco de Bruyn, and Marcel A T M van Vugt, and Floris Foijer
APOBEC3A drives STING-dependent metastasis.
December 2021, Nature cancer,
Christy Hong, and Michael Schubert, and Andréa E Tijhuis, and Marta Requesens, and Maurits Roorda, and Anouk van den Brink, and Lorena Andrade Ruiz, and Petra L Bakker, and Tineke van der Sluis, and Wietske Pieters, and Mengting Chen, and René Wardenaar, and Bert van der Vegt, and Diana C J Spierings, and Marco de Bruyn, and Marcel A T M van Vugt, and Floris Foijer
The cGAS-STING pathway drives type I IFN immunopathology in COVID-19.
March 2022, Nature,
Christy Hong, and Michael Schubert, and Andréa E Tijhuis, and Marta Requesens, and Maurits Roorda, and Anouk van den Brink, and Lorena Andrade Ruiz, and Petra L Bakker, and Tineke van der Sluis, and Wietske Pieters, and Mengting Chen, and René Wardenaar, and Bert van der Vegt, and Diana C J Spierings, and Marco de Bruyn, and Marcel A T M van Vugt, and Floris Foijer
cGAS-STING signaling pathway in gastrointestinal inflammatory disease and cancers.
January 2022, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Christy Hong, and Michael Schubert, and Andréa E Tijhuis, and Marta Requesens, and Maurits Roorda, and Anouk van den Brink, and Lorena Andrade Ruiz, and Petra L Bakker, and Tineke van der Sluis, and Wietske Pieters, and Mengting Chen, and René Wardenaar, and Bert van der Vegt, and Diana C J Spierings, and Marco de Bruyn, and Marcel A T M van Vugt, and Floris Foijer
Pharmacological Targeting of STING-Dependent IL-6 Production in Cancer Cells.
January 2021, Frontiers in cell and developmental biology,
Christy Hong, and Michael Schubert, and Andréa E Tijhuis, and Marta Requesens, and Maurits Roorda, and Anouk van den Brink, and Lorena Andrade Ruiz, and Petra L Bakker, and Tineke van der Sluis, and Wietske Pieters, and Mengting Chen, and René Wardenaar, and Bert van der Vegt, and Diana C J Spierings, and Marco de Bruyn, and Marcel A T M van Vugt, and Floris Foijer
FBXO38 deficiency promotes lysosome-dependent STING degradation and inhibits cGAS-STING pathway activation.
January 2024, Neoplasia (New York, N.Y.),
Copied contents to your clipboard!